The Food and Drug Administration on Wednesday approved Hoffman-La Roche's hepatitis C treatment Pegasys, a long-lasting form of interferon, The Washington Post reports. Current hepatitis C treatments include a combination regimen of interferon and ribavirin, with interferon being injected three times per week. Pegasys is injected only once per week. Clinical studies showed that Pegasys, combined with ribavirin, is more effective at lowering hepatitis C viral levels than the standard interferon-ribavirin treatment. Roche is currently seeking FDA approval of its ribavirin drug, Copegus. The company hopes to begin marketing a combination regimen of Pegasys and Copegus in the United States early next year.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved













